Literature DB >> 10654390

[Costs of coronary heart diseases over the remaining life time in coronary heart disease cases--an analysis of the current status of coronary heart disease cases in Germany from the social perspective].

G Klever-Deichert1, B Hinzpeter, E Hunsche, K W Lauterbach.   

Abstract

UNLABELLED: Cardiovascular diseases are the major cause of death not only in Germany. Coronary heart diseases result in substantial disability and loss of productivity and contribute to escalating costs of health care.
OBJECTIVE: It was our objective to estimate the costs of CHD for the German population from the perspective of the society. The characteristic of this approach is the calculating of costs until the approximated end of life.
METHODS: In the study, all health care costs concerning CHD in Germany were allocated to age, sex, health care sector and primary diagnosis on the basis of comprehensive data on morbidity, mortality, direct and indirect costs. For the estimate of indirect costs the human capital approach was taken. Considered as cases were all patients hospitalized in the reference year (1996). The costs of this cohort in 1996 and up to their protected end of life were estimated. It was taken into account that, in comparison to the general population, life expectancy of cases with risk factors or CHD would have been reduced. In calculating indirect costs, gender and age specific unemployment rates were considered. All future costs were discounted by 4% from the reference year onward.
RESULTS: Direct costs are approximately 39 billion DM discounted at 4%, indirect costs total 73 billion DM. The average cost per case (including morbidity and mortality) until the approximated end of life is nearly 125,000 DM.
CONCLUSION: In our cost analysis, the indirect costs are higher than the direct costs. For the future, it will be important to estimate the costs of prevalent cases until the end of life and to compare the influence of different interventions on these parameters and on the whole budget of the social security system.

Entities:  

Mesh:

Year:  1999        PMID: 10654390     DOI: 10.1007/s003920050381

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  5 in total

1.  Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany.

Authors:  Sarah Dewilde; Bernd Brüggenjürgen; Christoph Nienaber; Jochen Senges; Robert Welte; Stefan N Willich
Journal:  Eur J Health Econ       Date:  2011-04-12

2.  Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.

Authors:  B Brüggenjürgen; P Lindgren; B Ehlken; H-J Rupprecht; S N Willich
Journal:  Eur J Health Econ       Date:  2007-03

3.  Cost effectiveness of coronary angiography and calcium scoring using CT and stress MRI for diagnosis of coronary artery disease.

Authors:  Marc Dewey; Bernd Hamm
Journal:  Eur Radiol       Date:  2006-10-10       Impact factor: 5.315

4.  Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.

Authors:  Peter K Schädlich; Josef Georg Brecht; Badrudin Rangoonwala; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 5.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.